Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B- 428

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3585-3593

  Xing, Rosie Hongmei ^a   Mazar, Andrew ^b,c   Henkin, Jack ^b   Rabbani, Shafaat Ahmed ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c Angstrom Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR; TAMOXIFEN; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIDINES; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN ANTAGONISTS; FEMALE; NEOPLASM INVASIVENESS; RATS; RATS, INBRED F344; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TAMOXIFEN; THIOPHENES; TRANSCRIPTION, GENETIC; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030795071     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Russo, J., and Russo, I. H. The etiopathogenesis of breast cancer prevention. Cancer Lett., 90: 81-89, 1995.
2. Lippman, M. E., Bolan, G., and Huff, K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term culture. Cancer Res., 36: 4610-4618, 1976.
3. Clarke, R., Thompson, E. W., Leonessa, F., Lippman, J., McGarvey, M., Frandsen, T. L., and Brünner, N. Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res. Treat., 24: 227-239, 1993.
4. Horwitz, K. B. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr. Rev., 13: 146-163, 1992.
5. Jordan, V. C. Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res. Treat., 36: 267-285, 1995.
6. Lippman, M. E., Bolan, G., Monaco, M. E., Pinkus, L., and Engel, E. Model systems for the study of estrogen action in tissue culture. J. Steroid Biochem., 7: 1045-1051, 1976.
7. Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
8. Dickson, R. B., and Lippman, M. E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr. Rev., 8: 29-43, 1987.
9. Mullins, D. E., and Rohrlich, S. T. The role of proteinases in cellular invasiveness. Biochim. Biophys. Acta, 695: 177-214, 1983.
10. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
11. Vassali, J. D., and Pepper, M. S. Membrane proteases in focus. Nature (Lond.), 370: 14-15, 1994.
12. Danø, K., Behrendt, M., Brünner, N., Ellis, V., Plough, M., and Pyke, C. The urokinase receptor protein structure and role of plasminogen activator and cancer invasion. Fibrinolysis. 8: 189-202, 1994.
13. Quax, P. H. A., VanMuijen, G. N. P., Weening-Verhoeff, G. J. O., Lund, L. R., Danø, K., Ruiter, D. J., and Verheijen, J. H. Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J. Cell. Biol., 115: 191-199, 1991.
14. Hollas, W., Soravia, E., Mazar, A. P., Henkin, J., Blasi, F., and Boyd, D. Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem. J., 285: 629-634, 1992.
15. Achbarou, A., Kaiser, S., Tremblay, G., Sainte-Marie, L. G., Brodt, P., Goltzman, D., and Rabbani, S. A. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54: 2372-2377, 1994.
16. Jänicke, F., Schmitt, M., and Graeff, H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thrombosis Hemostasis, 17: 303-312, 1991.
17. Grøndahl-Hansen, J., Ralfkiaer, E., Kirkeby, L. T., Kristensen, P., Lund, L. R., and Danø, K. Localization of urokinase type plasminogen activator in stromal cells in adrenocarcinomas of the colon in humans. Am. J. Pathol., 138: 111-117, 1991.
18. Duggan, C., Maguire, T., McDermott, E., O'Higgins, H., Fennelly, J. J., and Duffy, M. J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer, 61: 597-600, 1995.
19. Xing, R. H., and Rabbani, S. A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer, 67: 423-429, 1996.
20. Fazioli, F., and Blasi, F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci., 15: 25-29, 1994.
21. Rabbani, S. A., Harakidas, P., Davidson, D. J., Henkin, J., and Mazar, A. P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer, 63: 840-845, 1995.
22. Alonso, D. F., Farias, E. F., Ladeda, V., Davel, L., Puricelli, L., and Bal De Kier Joffé, E. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res. Treat., 40: 209-223, 1996.
23. Towle, M. J., Lee, A., Emmanuel, C., Maduakor, C., Schwartz, C. E., Bridges, A. J., and Littlefield, B. A. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res., 53: 2553-2559, 1993.
24. Huynh, H. T., Tetenes, E., Wallace, L., and Pollak, M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res., 53: 1727-1730, 1993.
25. Price, J. E. Metastasis from human breast cancer cell lines. Breast Cancer Res. Treat., 39: 93-102, 1996.
26. Love, R. R. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J. Clin. Oncol., 7: 803-815, 1989.
27. Torczynski, R., Bollon, A. P., and Fuke, M. The complete nucleotide sequence of the rat 18S ribosomal RNA gene and comparison with the respective yeast and frog genes. Nucleic Acids Res., 11: 4879-4890, 1983.
28. Liu, D. F., and Rabbani, S. A. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate, 27: 269-275, 1995.
29. Liu, B., Goltzman, D., and Rabbani, S. A. Regulation of parathyroid hormone related peptide production in vitro by the red hypercalcemic Leydig cell tumor H.500. Endocrinology, 132: 1658-1664, 1993.
30. Pyke, C., Graem, N., Ralfkiaer, E., Ronne, E., Hoyer-Hansen, G., Brünner, N., and Danø, K. The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res., 53: 1911-1915, 1993.
31. Kobayashi, H., Gotoh, J., Shinohara, H., Moniwa, N., and Terao, T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb. Haemost., 71: 474-480, 1994.
32. Nielsen, B. S., Sehested, M., Timshel, S., Pyke, C., and Danø, K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest., 24: 168, 1996.
33. Elliott, E., and Sloane, B. F. The cysteine protease cathepsin B in cancer. Perspect. Drug Discovery Design, 6: 12-32, 1996.
34. Mbalaviele, G., Dunstan, C. R., Sasaki, A., Williams, P. J., Mundy, G. R., and Yoneda, T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res., 56: 4063-4070, 1996.
35. Pirinen, R., Lipponen, P., Aaltomaa, S., and Syrjanen, K. Prognostic value of epidermal growth factor expression in breast cancer. J. Cancer Res. Clin. Oncol., 123: 63-68, 1997.
36. Wang, Y., Jones, C. J., Dang, J. J., Liang, X., Olsen, J. E., and Doe, W. F. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett., 353: 138-142, 1994.
37. Shetty, S., Kumar, A., and Idell, S. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell. Biol., 17: 1075-1083, 1997.
38. Kalkhoven, E., Beraldi, E., Panno, M. L., De Winder, J., Thijssen, J. H. H., and Van Der Burg, B. Growth inhibition by anti-estrogens and progestins in TGF-β-resistant and -sensitive breast-tumor cells. Int. J. Cancer, 65: 682-687, 1996.
39. Pratt, S., and Pollak, M. N. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res., 53: 5193-5198, 1993.
40. Millon, R., Nicora, R., Muller, D., Eber, M., Klein-Soyer, C., and Abecassis, J. Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin. Exp. Metastasis, 7: 405-415, 1989.
41. Min, H. Y., Doyle, L. V., Vitt, C. R., Zandonella, C. L., Stratton-Thomas, J. R., Shuman, M. A., and Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res., 56: 2428-2433, 1996.
42. Gasparini, G. Biological and clinical role of angiogenesis in breast cancer. Breast Cancer Res. Treat., 36: 103-107, 1995.
43. Avery, R. L., Connor, T. B., Jr., and Farazdaghi, M. Systemic amiloride inhibits experimentally induced neovascularization. Arch. Opthalmol., 108: 1474-1476, 1990.